Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
02
09
2020
accepted:
17
11
2020
revised:
06
11
2020
pubmed:
5
12
2020
medline:
10
7
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2-10.52) and 50%. received reduced intensity conditioning with melphalan 140 mg/m
Identifiants
pubmed: 33273658
doi: 10.1038/s41409-020-01159-9
pii: 10.1038/s41409-020-01159-9
doi:
Substances chimiques
Melphalan
Q41OR9510P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1144-1150Références
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–107.
pubmed: 31735560
Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7:e447–e55.
pubmed: 32470437
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370–e80.
pubmed: 32213342
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl J Med. 2019;381:727–38.
pubmed: 31433920
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67.
pubmed: 32212178
Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. J Natl Compr Cancer Netw. 2019;17:1154–65.
Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183–96.
pubmed: 17241924
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–7.
pubmed: 8649495
Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE. Newly diagnosed myeloma in 2020. Am Soc Clin Oncol Educ Book. 2020;40:1–15.
pubmed: 32315239
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–74.
pubmed: 25628469
pmcid: 4375104
Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, et al. Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. Am J Hematol. 2020;95:759–65.
pubmed: 32242970
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61.
pubmed: 28453614
Ghilardi G, Pabst T, Jeker B, Müller R, Cairoli A, Müller AMS, et al. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2019;54:1029–37.
pubmed: 30390061
Marini C, Maia T, Bergantim R, Pires J, Aguiar E, Guimarães JE, et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Ann Hematol. 2019;98:369–79.
pubmed: 30368589
Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, et al. Efficacy and safety of autologous stem cell transplantation in patients aged ≥65 years with multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2019;54:1595–604.
pubmed: 30783208
Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25:189–95.
pubmed: 24356629
Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209–15.
pubmed: 25387088
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–e68.
pubmed: 32359506
Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589–97.
pubmed: 30653422
pmcid: 6553842
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
pubmed: 25439696
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62.
pubmed: 27002115
pmcid: 4920674
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.
pubmed: 27511158
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M. SEER cancer statistics review, 1975–2016. https://seer.cancer.gov/csr/1975_2017/results_merged/topic_med_age.pdf .
Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83:1131–8.
pubmed: 18828972
Wiebach H, Gezer D, Brummendorf TH, Crysandt M, Wilop S. Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: a single-center retrospective analysis. Current Res Transl Med. 2020;68:139–44.
Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, et al. Autologous hematopoietic cell transplantation in patients with multiple myeloma: effect of age. Clin Lymphoma Myeloma Leukemia. 2017;17:165–72.
Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020;126:5077–87.
pubmed: 32965680
Yip HM, Yong K, De-Silva D, Rabin N. Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma. Hematol Oncol Stem Cell Therapy. 2020. https://doi.org/10.1016/j.hemonc.2020.01.001 .
Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, et al. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol 2017;99:532–5.
pubmed: 28895206
Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016;82:149–59.
pubmed: 26879446
pmcid: 4917807
Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36:1323–9.
pubmed: 29558277
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103:197–211.
pubmed: 29217780
pmcid: 5792264
Dold SM, Möller MD, Ihorst G, Langer C, Pönisch W, Mügge LO, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2020. https://doi.org/10.3324/haematol.2020.254235 .
Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6:e154–e66.
pubmed: 30738834
pmcid: 6391517
Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91:1129–34.
pubmed: 27508522
pmcid: 5129512
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, et al. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin. Lymphoma Myeloma Leukemia 2012;12:423–32.
Murillo A, Cronin AM, Laubach JP, Hshieh TT, Tanasijevic AM, Richardson PG, et al. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019;10:486–9.
pubmed: 30472368
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132–41.
pubmed: 31836199
Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood. 2020;136:936–45.
pubmed: 32325490
pmcid: 7441167
Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018;8:125.
pubmed: 30538223
pmcid: 6289963
Fiala MA, Foley NC, Zweegman S, Vij R, Wildes TM. The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. J Geriatric Oncol. 2020;11:1274–8.
Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, et al. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leuk Lymphoma 2019;60:3536–43.
pubmed: 31282244
Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282–7.
pubmed: 29296944
pmcid: 5727774
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl J Med. 2019;380:2104–15.
pubmed: 31141632